Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
297 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05097911 | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | active not recruiting | Phase 1 | 33 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT05381038 | Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI | recruiting | Phase 1 / Phase 2 | 10 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 |
| clinicaltrials |
| NCT05723640 | The Safety and Dosimetry Study of 177Lu-LNC1004 Injection | completed | Phase 1 | 11 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT06463782 | Clinical Study of 68Ga-LNC1007 Injection PET/CT | completed | Phase 1 | 8 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT02900651 | Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | terminated | Phase 1 | 139 | Novartis PharmaceuticalsINDUSTRY | 10 | Aug 11, 2025 | clinicaltrials |
| NCT04051827 | Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 26 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 28, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06513624 | ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers(ETC-159-02) | recruiting | Phase 1 | 16 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03772561 | Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies(MEDIPAC) | recruiting | Phase 1 | 40 | National University Hospital, SingaporeOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT03853109 | AMG 404 in Patients With Advanced Solid Tumors | completed | Phase 1 | 171 | AmgenINDUSTRY | 13 | Jul 20, 2025 | clinicaltrials |
| NCT02204072 | BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 | 120 | Boehringer IngelheimINDUSTRY | 8 | Jul 15, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02191891 | Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 | 32 | Boehringer IngelheimINDUSTRY | 4 | Jun 25, 2025 | clinicaltrials |
| NCT02303821 | Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 1 | 141 | AmgenINDUSTRY | 33 | Jun 4, 2025 | clinicaltrials |
| NCT03037385 | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) | completed | Phase 1 / Phase 2 | 590 | Hoffmann-La RocheINDUSTRY | 13 | May 31, 2025 | clinicaltrials |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC). | terminated | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | May 18, 2025 | clinicaltrials |
| NCT02913313 | A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 101 | Bristol-Myers SquibbINDUSTRY | 8 | Apr 20, 2025 | clinicaltrials |
| NCT05687747 | Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma | recruiting | Phase 1 | 100 | National University Hospital, SingaporeOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT02689284 | Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer | completed | Phase 1 / Phase 2 | 95 | MacroGenicsINDUSTRY | 5 | Mar 17, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT02716012 | First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer(OUTREACH) | unknown | Phase 1 | 75 | Mina Alpha LimitedINDUSTRY | 3 | Mar 10, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT06054477 | Study of ALE.C04 in Patients With Head and Neck Cancer | terminated | Phase 1 / Phase 2 | 21 | Alentis Therapeutics AGINDUSTRY | 8 | Feb 17, 2025 | clinicaltrials |
| NCT04862780 | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | terminated | Phase 1 | 177 | Blueprint Medicines CorporationINDUSTRY | 10 | Feb 10, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT03948763 | A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001) | terminated | Phase 1 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Jan 28, 2025 | clinicaltrials |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies. | terminated | Phase 1 | 127 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT02108964 | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | completed | Phase 1 / Phase 2 | 225 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 11, 2024 | clinicaltrials |
| NCT03846310 | A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer(ARC-4) | completed | Phase 1 | 77 | Arcus Biosciences, Inc.INDUSTRY | 4 | Dec 9, 2024 | clinicaltrials |
| NCT03813394 | Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC(2018/00947) | active not recruiting | Phase 1 / Phase 2 | 48 | National University Hospital, SingaporeOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT05302037 | Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)(ANGELICA) | recruiting | Phase 1 | 12 | CytoMed Therapeutics Pte LtdINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT03215511 | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | completed | Phase 1 | 81 | BayerINDUSTRY | 10 | Oct 30, 2024 | clinicaltrials |
| NCT02325739 | FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | completed | Phase 1 / Phase 2 | 172 | Novartis PharmaceuticalsINDUSTRY | 11 | Oct 21, 2024 | clinicaltrials |
| NCT02521844 | A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours | active not recruiting | Phase 1 | 89 | EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesOTHER_GOV | 2 | Oct 8, 2024 | clinicaltrials |
| NCT04645069 | ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Adagene IncINDUSTRY | 3 | Aug 14, 2024 | clinicaltrials |
| NCT01970865 | A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations | completed | Phase 1 / Phase 2 | 364 | PfizerINDUSTRY | 14 | Aug 12, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT02314052 | Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 21 | Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyINDUSTRY | 3 | Jul 11, 2024 | clinicaltrials |
| NCT05538572 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | completed | Phase 1 | 22 | Prelude TherapeuticsINDUSTRY | 2 | Jul 1, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT03172416 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis(PIPAC) | unknown | Phase 1 | 21 | National University Hospital, SingaporeOTHER | 2 | May 29, 2024 | clinicaltrials |
| NCT05395910 | Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel In Patients With Peritoneal Carcinomatosis | unknown | Phase 1 | 36 | National University Hospital, SingaporeOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT02508467 | A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | completed | Phase 1 | 146 | Blueprint Medicines CorporationINDUSTRY | 12 | Apr 12, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT01543698 | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 189 | PfizerINDUSTRY | 9 | Mar 13, 2024 | clinicaltrials |
| NCT04961632 | Dose-determining and Dose-confirmatory Study to Investigate the Optimal Dose of Tamoxifen in Breast Cancer Patients According to Genotype Status of TCF20 rs932376 | unknown | Phase 1 | 75 | National Cancer Centre, SingaporeOTHER | 1 | Feb 1, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials